Thiazide-induced hypocalciuria is accompanied by a decreased expression of Ca2+ transport proteins in kidney  by Nijenhuis, Tom et al.
Kidney International, Vol. 64 (2003), pp. 555–564
Thiazide-induced hypocalciuria is accompanied by a decreased
expression of Ca2 transport proteins in kidney
TOM NIJENHUIS, JOOST G.J. HOENDEROP, JOHANNES LOFFING, ANNEMIETE W.C.M. VAN DER KEMP,
CAREL H. VAN OS, and RENE´ J.M. BINDELS
Department of Cell Physiology, Nijmegen Center for Molecular Life Sciences, University Medical Center Nijmegen, Nijmegen,
The Netherlands; and Institute of Anatomy, University of Zurich, Zurich, Switzerland
Thiazide-induced hypocalciuria is accompanied by a decreased
expression of Ca2 transport proteins in kidney.
Introduction. Thiazide diuretics have the unique characteris-
tic of increasing renal Na excretion, while decreasing Ca2
excretion. However, the molecular mechanism responsible for
this thiazide-induced hypocalciuria remains unclear. The pres-
ent study investigates the effect of thiazides on the expression
of the proteins involved in active Ca2 transport as well as the
role of extracellular volume (ECV) status.
Methods. Hydrochlorothiazide (HCTZ), 12 mg/24 hours,
was administered during 7 days to Wistar rats by osmotic mini-
pumps. In addition, ECV contraction was either prevented by
Na repletion or induced by a low-salt diet. Expression levels
of the proteins involved in active Ca2 transport [i.e., epithelial
Ca2 channel (TRPV5/ECaC1), calbindin-D28K, Na/Ca2 ex-
changer (NCX1)], as well as the thiazide-sensitive Na Cl co-
transporter (NCC) were determined by real-time quantitative
polymerase chain reaction (PCR) and semiquantitative immu-
nohistochemistry.
Results. HCTZ significantly reduced urinary Ca2 excretion
(22%  5% relative to controls). Hematocrit was significantly
increased, confirming ECV contraction. In addition, Nadeple-
tion virtually abolished Ca2 excretion (8%  1%), while Na
repletion during HCTZ treatment prevented both ECV con-
traction and hypocalciuria. HCTZ significantly decreased mRNA
expression of TRPV5 (71%  6%), calbindin-D28K (53% 
6%), NCX1 (51%  8%) and NCC (50%  11%), regardless
of ECV status or calciuresis. Immunohistochemistry revealed
reduced TRPV5 (43%  2%), calbindin-D28K (59%  1%)
and NCC (56% 4%) abundance. Furthermore, during HCTZ
treatment, the subset of tubules coexpressing NCC and calbin-
din-D28K was significantly reduced (43% 5%) and a disturbed
cellular localization of NCC was observed.
Conclusion. These data suggest that ECV contraction is a
critical determinant of the thiazide-induced hypocalciuria,
which is accompanied by a decreased expression of Ca2 trans-
port proteins.
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Thiazides are among the most widely prescribed drugs
today, particularly by being the mainstay of first-line
therapy in hypertension. In addition, these diuretics have,
in contrast to loop diuretics, the unique characteristic
of increasing Ca2 reabsorption, while decreasing Na
reabsorption [1]. This hypocalciuric effect provides ther-
apeutic opportunities in for instance idiopathic hypercal-
ciuria and nephrolithiasis. Furthermore, thiazides have
been shown to increase bone mineral density and de-
crease fracture risk, spiking interest in the favorable
long-term effects of these diuretics in counteracting os-
teoporosis [2–4]. Thiazides increase renal Na excretion
by inhibiting the NaCl cotransporter (NCC or thiazide
receptor) present in the apical membrane of distal convo-
luted tubule (DCT) cells [5]. Surprisingly, the exact mo-
lecular mechanism responsible for the thiazide-induced
hypocalciuria remains unclear. Increased passive proxi-
mal Ca2 reabsorption as well as direct stimulation of
active Ca2 transport in the DCT have been suggested
to explain the hypocalciuric effects of chronic thiazide
administration [6–8].
The inhibition of Na reabsorption in DCT by thia-
zides results in increased renal salt and water loss and
thereby decreases extracellular volume (ECV) [5]. This
ECV contraction has been shown to result in a compen-
satory enhancement of proximal Na reabsorption,
thereby increasing the electrochemical gradient driving
passive Ca2 transport in proximal tubule segments [9].
Therefore, the hypocalciuric effect of chronic thiazide
administration was postulated to be the result of an en-
hancement of passive paracellular Ca2 reabsorption sec-
ondary to ECV contraction [10, 11].
Previously, acute administration of thiazides into the
tubular lumen was shown to stimulate transcellular Ca2
transport in DCT [1]. Subsequently, several mechanisms
have been postulated to explain the hypocalciuria of
chronic thiazide treatment by a similar stimulatory effect
[7, 12]. Stimulation of apical Ca2 entry has been sug-
gested, mediated by hyperpolarization of the plasma
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membrane secondary to NCC inhibition. After the re-
cent identification and characterization of the epithelial
Ca2 channel TRPV5 (previously named ECaC1) as the
rate-limiting apical entry step in transepithelial Ca2
transport, several authors postulated that the molecular
and electrophysiologic properties of TRPV5 were in line
with the aforementioned hypothesis [10, 13, 14]. Alterna-
tively, enhanced basolateral Na/Ca2 exchange by up-
regulation of the Na/Ca2 exchanger (NCX1), second-
ary to decreased intracellular Na concentration, has also
been suggested as the principal responsible mechanism
[7, 10]. Both hypotheses rely on substantial colocalization
in DCT of NCC and the proteins involved in active Ca2
transport. Extensive immunohistochemical studies dem-
onstrated that NCC and TRPV5 only overlap in part,
whereas the Ca2 transporters (i.e., TRPV5, calbindin-
D28K, NCX1, and PMCA1b) completely colocalize [6, 15].
The aim of the present study was to determine the
effect of chronic thiazide treatment and the ECV status
on the expression levels of the major Ca2 transporters in
the kidney. To this end, rats were treated for 7 days with
hydrochlorothiazide (HCTZ) and housed in metabolic
cages. Subsequently, the expression of the Ca2 transport-
ers was determined by real-time polymerase chain reac-
tion (PCR) and immunohistochemical analysis.
METHODS
Animal studies
Young adult male Wistar rats, initial weight 200 to
225 g, were housed individually in metabolic cages en-
abling 24-hour urine collection. The animals were kept in
a light- and temperature-controlled room with ad libitum
access to standard pelleted chow and deionized water,
and were maintained under these same conditions during
a 4-day run-in period. Thereafter, rats were randomized
into five groups: (1) a control group (controls; N  6),
(2) a group to receive only thiazide treatment (HCTZ;
N  5), (3) a group to receive thiazide treatment as
well as oral NaCl/KCl repletion via the drinking water
(HCTZ/Na-repleted; N 5), (4) a Na-depleted group
fed a synthetic low-sodium diet (Na-depleted; N  5),
and (5) a Na-depleted group receiving thiazide treat-
ment (HCTZ/Na-depleted; N  5). Starting from the
fifth day, all animals were ration-fed (20 g/day) either
the standard rat chow [0.25% (wt/vol) NaCl; 1% (wt/
vol) Ca2] or a Na-depleted diet [0.02% (wt/vol) NaCl;
1% (wt/vol) Ca2], rendering dietary intake equal in all
animals with the exception of NaCl. On the ninth day,
designated animals were anaesthetized and either had
osmotic minipumps (model 2ML1; Alzet, Palo Alto, CA,
USA) containing HCTZ implanted subcutaneously in
the neck region, or were sham-operated, receiving mini-
pumps containing vehicle only. Osmotic minipumps con-
tained HCTZ in 50% (vol/vol) dimethyl sulfoxide
(DMSO), resulting in continuous rate–controlled deliv-
ery of HCTZ at a dose of 12 mg/24 hours. While this
dosage is, relative to body weight, higher than the dosage
used in humans in clinical practice, pilot experiments
indicated this to be the lowest dosage resulting in a sig-
nificant diuresis in these rats. HCTZ was preferred over
other thiazides because of its limited carbonic anhydrase
activity. The animals in the HCTZ/Na-repleted group
were switched to drinking water containing 0.9% (wt/
vol) NaCl and 0.1% (wt/vol) KCl in deionized water the
next day. Six days postimplantation, body weight was
determined, blood samples were taken, and the animals
were sacrificed. Kidney cortex was sampled and immedi-
ately frozen in liquid nitrogen. In addition, kidney cortex
was fixated for immunohistochemistry by immersion in
1% (wt/vol) periodate-lysine-paraformaldehyde (PLP)
for 2 hours and 15% (wt/vol) sucrose in phosphate-buf-
fered-saline (PBS) overnight. Subsequently, samples
were stored at –80C until further processing. The Ani-
mal Ethics Board of the University Medical Center Nij-
megen approved all experimental procedures.
Analytic procedures
Serum and urine Ca2 concentrations were deter-
mined using a colorimetric assay as described previously
[16]. Serum and urine [Na] and [K] were measured
flame-spectrophotometrically (Eppendorf FCM 6343,
Hamburg, Germany). Hematocrit was determined using
a standard centrifugation protocol [17].
Real-time quantitative PCR
Total RNA was extracted from kidney cortex using
TriZol Total RNA Isolation Reagent (Gibco BRL,
Breda, The Netherlands). The obtained RNA was sub-
jected to DNAse treatment to prevent genomic DNA
contamination. Thereafter, 2 g RNA was reverse tran-
scribed by Moloney-Murine Leukemia Virus-Reverse
Transcriptase (M-MLV-RT; Gibco BRL) as described
previously [18]. The obtained cDNA was used to deter-
mine renal TRPV5, calbindin-D28K, NCC, and NCX1
mRNA levels, as well as mRNA levels of the housekeep-
ing gene hypoxanthine-guanine phosphoribosyl trans-
ferase (HPRT) as an endogenous control. Expression
levels were quantified by real-time quantitative PCR on
an ABI Prism 7700 Sequence Detection System (PE
Biosystems, Rotkreuz, Switzerland). Primer and probe
sequences are listed in Table 1 (Biolegio, Malden, The
Netherlands).
Immunohistochemistry
Immunohistochemical staining was performed as de-
scribed previously [19]. In short, 7 m sections of PLP-
fixed frozen kidney cortex samples were stained for
TRPV5, calbindin-D28K, and NCC. TRPV5 staining in-
volved immersion of the kidney sections in boiled citrate
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). target retrieval buffer (0.01 mol/L sodium citrate and
0.01 mol/L citric acid, pH 6.0), which was then left to
cool for 30 minutes, and subsequent incubation in 0.3%
(vol/vol) H2O2 in buffer (0.15 mol/L NaCl and 0.1 mol/L
Tris-HCl, pH 7.5) for 30 minutes. Sections were incubated
for 16 hours at 4C with primary antibody, affinity-puri-
fied guinea pig anti-TRPV5 antiserum (1:1000) [19], or
mouse anti-calbindin-D28K (Swant, Bellinzona, Switzer-
land) (1:500) and rabbit anti-NCC (1:300), respectively.
After incubation with biotin-coated goat anti-guinea pig
secondary antibody, TRPV5 was visualized using a tyra-
mide signal amplification kit (NEN Life Science Prod-
ucts, Zaventem, Belgium). For detection of calbindin-
D28K and NCC, sections were incubated with an Alexa
488–conjugated goat anti-rabbit or an Alexa 594–conju-
gated goat anti-mouse secondary antibody. To quantify
protein expression levels, the mean number of immuno-
positive tubules per microscopic field was determined.
Images were made using a Nikon Diaphot confocal laser
scanning microscope (Tokyo, Japan; MRC-1000; Bio-
Rad, Richmond, CA, USA). Anti-serum against NCC
was obtained by immunization of rabbits with a keyhole
limpet hemocyanin-coupled synthetic peptide corre-
sponding to a conserved amino acid sequence present
within the N-terminal tail of rat, mouse, and human NCC
(NH2-CLPGEPRKVRPTLADLH-COOH). The anti-
serum was affinity-purified according to standard proce-
dures (Pineda Ab-Production, Berlin, Germany). In so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) analysis of mouse kidney homogenates,
the affinity-purified anti-serum recognized a single band
at 190 kD that was not seen with kidney homogenates
of NCC knockout mice [20].
Immunoblotting
Kidney cortex sections were homogenized in homoge-
nization buffer A (HbA) [20 mmol/L Tris/HCl, pH 
7.4), 5 mmol/L MgCl, 5 mmol/L NaH2PO4, 1 mmol/L
ethylenediaminetetraacetic acid (EDTA), 80 mmol/L su-
crose, 1 mmol/L phenylmethylsulfonyl fluoride (PMSF),
and 5 g/mL leupeptin and pepstatin]. Protein concen-
tration of the homogenates was determined (Bio-Rad
Protein Assay; Bio-Rad Munchen, Germany) and sam-
ples were normalized accordingly. Subsequently, 50 g
protein samples were separated on 12% (wt/vol) SDS-
PAGE gels and blotted to polyvinylidine difluoride
(PVDF)-nitrocellulose membranes (Immobilon-P; Milli-
pore Corporation, Bedford, MA, USA). Blots were incu-
bated for 1 hour with mouse anti-calbindin-D28K (Swant)
(1:10.000). Thereafter, blots were incubated with a goat
anti-mouse peroxidase coupled secondary antibody and
immunoreactive protein was detected using the chemilu-
minescence method. Immunopositive bands were scanned
using an imaging densitometer (Bio-Rad Gs-690) to de-
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Table 2. Urine and serum analyses, hematocrit, and body weight
Controls HCTZ HCTZ/Na-repleted Na-depleted HCTZ/Na-depleted
Urine
Diuresis % 10019 19310a 36628a 12723 43343a
Ca2 excretion % 10030 225a 10638 81a 184a
Na excretion % 1009 11115 60980a 173a 154a
K excretion % 10013 1369 17813a 12716 12420
Creatinine clearance mL/min/kg 0.410.14 0.360.19 0.390.16 0.340.08 0.410.13
Serum
Ca2 mmol/L 2.200.05 2.120.05 2.160.04 2.180.02 2.240.05
Na mmol/L 135.30.7 133.11.0 135.70.6 131.61.9 131.12.2a
K mmol/L 5.20.2 4.80.2 4.80.1 4.90.1 4.20.3a
Creatinine lmol/L 361 371 351 341 381
Hematocrit l/L 0.380.01 0.450.01a 0.390.01 0.440.01a 0.440.01a
Weight % 1002 923a 952 1012 902a
Controls, sham-operated animals; HCTZ, hydrochlorothiazide 12 mg/24 hours; HCTZ/Na-repleted, HCTZ 12 mg/24 hours supplemented with NaCl/KCl via the
drinking water; Na-depleted, animals fed the low-sodium diet (0.02% [wt/vol] NaCl); and HCTZ/Na-depleted, Na-depleted animals receiving 12 mg/24 hours
HCTZ. For urine electrolyte values and body weight, data are presented relative to the mean of controls (100% refers to diuresis of 8 mL/24 hours, Ca2 excretion
of 9 mol/24 hours, Na excretion of 0.9 mmol/24 hours, and K excretion of 1.8 mmol/day). Data are presented as mean  SEM.
aP  0.05 vs. controls
termine pixel density (Molecular Analyst Software; Bio-
Rad Laboratories, Hercules, CA, USA).
Statistical analysis
Data are expressed as means  SEM. Statistical com-
parisons were tested by one-way analysis of variance
(ANOVA) and Fisher’s multiple comparison. P values
less than 5% were considered statistically significant. All
analyses were performed using the Statview Statistical
Package software (Power PC, version 4.51, Berkley, CA,
USA) on a Macintosh computer.
RESULTS
Urine and serum analysis
Electrolyte values of the serum and 24-hour urine sam-
ples, creatinine clearance, hematocrit, and body weight
data of the five experimental groups are shown in Table
2. In the HCTZ group, a significant hypocalciuria was
induced. Urine volume was significantly increased,
whereas Na and K excretion did not significantly differ
from controls. Hematocrit was significantly increased,
while body weight in these animals was significantly re-
duced. In the HCTZ/Na-repleted animals, oral supple-
mentation of NaCl/KCl completely prevented the thia-
zide-induced hypocalciuria. Likewise, hematocrit and
body weight in these animals did not significantly differ
from controls, whereas urine volume, Na and K excre-
tion were significantly enhanced. Interestingly, Ca2 ex-
cretion was virtually abolished by Na depletion, mim-
icking the action of thiazides. Similarly, in the HCTZ/
Na-depleted group, Ca2 excretion was significantly de-
creased relative to controls. In addition, hematocrit was
significantly increased in both the Na-depleted and
HCTZ/Na-depleted animals, whereas body weight was
significantly reduced in the HCTZ/Na-depleted ani-
mals, but unaffected in the Na-depleted group. Of note,
the inhibition of the calciuresis was comparable in the
HCTZ, Na-depleted, and HTCZ/Na-depleted groups.
Serum levels of Ca2, Na, and K were not significantly
affected in the experimental groups, except in HCTZ/
Na-depleted animals, a small, albeit significant, de-
crease of serum K concentration was observed. Serum
creatinine levels and creatinine clearance were not sig-
nificantly different between the various groups.
Real-time quantitative PCR
Kidney cortex mRNA levels of the Ca2 transport
proteins and NCC were determined by real-time quanti-
tative PCR (Fig. 1). In all HCTZ-treated groups, chronic
HCTZ administration consistently and significantly de-
creased mRNA expression of TRPV5, calbindin-D28K,
NCX1, and NCC. There were no significant differences
in expression levels between the three HCTZ-treated
groups. On the contrary, expression of TRPV5, calbin-
din-D28K, and NCC in the Na-depleted group did not
significantly differ from controls, whereas NCX1 mRNA
expression was reduced.
Immunohistochemistry
To assess whether the decreased mRNA levels resulted
in reduced protein expression, protein abundance was
semiquantified by immunohistochemistry. Figure 2 shows
that the above-mentioned results are indeed accompa-
nied by similar effects on the protein level. A reduced
protein expression of TRPV5, calbindin-D28K, and NCC
was consistently observed in all HCTZ-treated groups. In
contrast, in the Na-depleted group, protein expression
levels did not significantly differ from controls.
Interestingly, in addition to the characteristic apical
NCC staining, several tubules in HCTZ-treated animals
displayed a disturbed immunopositive staining [21, 22].
In these tubules NCC was not, as in controls (Fig. 3A),
localized to the apical domain, but a diffuse intracy-
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Fig. 1. Effect of hydrochlorothiazide (HCTZ) and extracellular volume
(ECV) status on mRNA expression levels of distal convoluted tubule
(DCT) transport proteins. mRNA expression levels of TRPV5 (A ),
calbindin-D28K (B ), Na Cl cotransporter (NCC) (C ), and Na/Ca2
exchanger (NCX1) (D ) in kidney cortex were determined by real-time
quantitative polymerase chain reaction (PCR). Results are presented
relative to controls. Controls, sham-operated animals; HCTZ, 12 mg/24
hours HCTZ; HCTZ/Na-repleted, 12 mg/24 hours HCTZ supple-
mented with NaCl/KCl via the drinking water; Na-depleted, animals
fed the low-sodium diet [0.02% (wt/vol) NaCl]; and HCTZ/Na-depleted,
Na-depleted animals receiving 12 mg/24 hours HCTZ. Data are pre-
sented as means  SEM. *P  0.05 vs. controls.
toplasmic distribution was apparent (Fig. 3B). This dis-
turbed staining pattern was never observed in kidney
cortex sections of rats not receiving HCTZ (i.e., the
control and Na-depleted groups).
Figure 4 depicts that the population of tubules co-
expressing NCC and calbindin-D28K was significantly de-
creased (	twofold) in the three HCTZ-treated groups,
whereas during Na depletion this decrease was not ob-
served. A similar concomitant down-regulation was de-
tected for NCC and TRPV5 (data not shown).
Immunoblotting
To confirm the semiquantitative determination of pro-
tein abundance by immunohistochemistry, immunoblot-
ting was performed for calbindin-D28K as shown in Figure
5. A significant reduction in calbindin-D28K protein abun-
dance was observed in all thiazide-treated animals. Den-
sitometric analysis of the individual immunoblots revealed
significantly reduced calbindin-D28K protein expression
levels in the HCTZ (61%  7%), HCTZ/Na-repleted
(52%  5%), and HCTZ/Na-depleted (60%  5%)
groups, whereas the protein expression in the Na-de-
pleted group (94%  3%) did not significantly differ
from controls (100%  4%). These data demonstrated
that protein abundance as determined by immunoblot-
ting is consistent with the immunohistochemical results
and confirmed the significant down-regulation of calbin-
din-D28K in the thiazide-treated animals.
DISCUSSION
In the present study, chronic HCTZ treatment induced
a significant hypocalciuria that was accompanied by ECV
contraction. Interestingly, a similar reduction in urinary
Ca2 excretion was observed during Na depletion, while
prevention of ECV contraction during HCTZ treatment
prohibited the development of hypocalciuria. Further-
more, HCTZ consistently decreased the mRNA expres-
sion and protein abundance of several transporters re-
sponsible for active Ca2 reabsorption, regardless of
volume status or calciuresis. Taken together, this sug-
gests that ECV contraction is a critical determinant of the
thiazide-induced hypocalciuria, which is accompanied by
decreased expression of proteins involved in the active
Ca2 transport process.
In this study, the HCTZ-induced hypocalciuria was
accompanied by a significant increase in hematocrit and
concomitant decrease in body weight, confirming that
ECV contraction occurred. Since Na depletion resulted
in a similar hypocalciuria and hypovolemia, it is tempting
to speculate that ECV contraction by itself is responsible
for the thiazide-induced hypocalciuria. This is further
supported by our finding that Na repletion during
HCTZ treatment, thereby preventing the ECV contrac-
tion, normalized the Ca2 excretion. In the literature,
volume contraction has been suggested as a causative
factor in thiazide-induced hypocalciuria [7, 10]. The un-
derlying mechanism is a compensatory enhancement of
proximal Na reabsorption, observed both in volume
contraction by diuretics and Na restriction [9, 23–25],
which leads to an increase in the electrochemical driving
force for passive Ca2 reabsorption [26]. Indeed, Walter
and Shirley [9] showed an increased Na reabsorption
by the proximal tubule secondary to HCTZ-induced Na
depletion. Furthermore, it is a general finding that during
chronic thiazide treatment natriuresis normalizes and
volume balance is eventually restored, which possibly
results from a persistently increased proximal reabsorp-
tion of Na [9]. Therefore, hypocalciuria can continue
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Fig. 3. Disturbed distribution of the Na Cl cotransporter (NCC) in
hydrochlorothiazide (HCTZ)-treated animals. Detail of distal convo-
luted tubule (DCT) showing NCC immunopositive staining of control
(A) and HCTZ-treated (B) rats demonstrating that the characteristic
apical NCC signal as shown in the controls is lost in a portion of
tubules present in the HCTZ-treated rats. Instead, a diffuse intracellular
appearance is visible (arrows).
Fig. 4. Hydrochlorothiazide (HCTZ) treatment reduced the amount of
Na Cl cotransporter (NCC) and calbindin-D28K coexpressing tubules.
Number of tubules coexpressing NCC and calbindin-D28K was deter-
mined by immunohistochemistry and presented relative to controls.
Controls, sham-operated animals; HCTZ, 12 mg/24 hours HCTZ;
HCTZ/Na-repleted, 12 mg/24 hours HCTZ supplemented with NaCl/
KCl via the drinking water; Na-depleted, animals fed the low-sodium
diet [0.02% (wt/vol) NaCl]; and HCTZ/Na-depleted, Na-depleted
animals receiving 12 mg/24 hours HCTZ. Data are presented as mean
SEM. *P  0.05 vs. controls.

Fig. 2. Effect of hydrochlorothiazide (HCTZ) and extracellular volume (ECV) status on protein abundance of distal convoluted tubule (DCT)
transport proteins. Protein expression of TRPV5 (A ), calbindin-D28K (B ), and Na Cl cotransporter (NCC) (C ) in kidney cortex were determined
by immunohistochemistry and presented relative to controls. Controls, sham-operated animals; HCTZ, 12 mg/24 hours HCTZ; HCTZ/Na-repleted,
12 mg/24 hours HCTZ supplemented with NaCl/KCl via the drinking water; Na-depleted, animals fed the low-sodium diet [0.02% (wt/vol) NaCl];
and HCTZ/Na-depleted, Na-depleted animals receiving 12 mg/24 hours HCTZ. Data are presented as means  SEM. * P  0.05 vs. controls.
Fig. 5. Hydrochlorothiazide (HCTZ) treatment reduced calbindin-D28K
protein abundance as determined by immunoblotting. Immunoblots for
calbindin-D28K of individual kidney samples. Controls, sham-operated
animals; HCTZ, 12 mg/24 hours HCTZ; HCTZ/Na-repleted, 12 mg/24
hours HCTZ supplemented with NaCl/KCl via the drinking water; Na-
depleted, animals fed the low-sodium diet [0.02% (wt/vol) NaCl]; and
HCTZ/Na-depleted, Na-depleted animals receiving 12 mg/24 hours
HCTZ.
despite a restored volume balance during chronic thia-
zide treatment. ECV contraction prior to thiazide admin-
istration was shown to result in an accelerated and more
pronounced hypocalciuric response [26]. The reverse
also holds true, since ECV expansion has been shown
to induce hypercalciuria by a mechanism dependent on
inhibition of proximal Na reabsorption [27–29]. Fur-
thermore, in hypertension a high prevalence of hypercal-
ciuria is reported [30]. In these hypercalciuric situations,
thiazide diuretics successfully normalized the Ca2 excre-
tion. Moreover, the mild diuretic amiloride, which inhib-
its Na reabsorption in the collecting system, is known
to enhance Ca2 reabsorption and to potentiate the Ca2-
sparing effects of thiazides [31]. This favors a general
mechanism, not restricted to DCT, underlying diuretic-
induced hypocalciuria. Together with our findings this
suggests that ECV contraction is an important determi-
nant of the chronic thiazide-induced hypocalciuria.
Costanzo and Windhager [1] showed in pioneering
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micropuncture and microperfusion experiments that
chlorothiazide could stimulate transcellular Ca2 trans-
port in DCT when directly instilled in the tubular lumen.
It is, however, important to distinguish acute from
chronic effects of thiazide diuretics. Acute administra-
tion results in a marked natriuresis and a decrease of
the urinary Ca2/Na ratio, while the net Ca2 excretion
has been shown to either decrease, remain at control
levels, or increase [7, 32]. Chronic administration, how-
ever, produces the overt thiazide-induced hypocalciuria.
The aforementioned microperfusion studies were per-
formed during acute thiazide administration and these
data are, therefore, restricted to the acute diuretic effects
[1]. Whether this process contributes to the chronic hypo-
calciuric effect of thiazides, studied in this paper, is not
clear. However, several theories, emphasizing an activa-
tion of transcellular Ca2 transport processes in DCT,
were advanced to explain the hypocalciuria during
chronic thiazide treatment. NCC inhibition leading to
decreased Cl entry could reduce the electrogenic exit
of Cl across the basolateral membrane. This has been
suggested to result in hyperpolarization of the apical
membrane and thereby enhance Ca2 entry from the
tubular lumen [7, 10, 33]. The observation that Ca2
currents through the apical Ca2 channel TRPV5 are
maximal at hyperpolarizing membrane potentials appar-
ently supports this hypothesis [14]. However, the de-
creased TRPV5 expression consistently observed during
HCTZ treatment does not support stimulation of apical
Ca2 entry by thiazides. Furthermore, thiazide-induced
hyperpolarization has been demonstrated in the basolat-
eral membrane only and it is unclear how this hyperpo-
larization translates to the proposed apical effect [13].
Alternatively, it has been suggested that stimulation of
active Ca2 reabsorption by thiazides is mediated by
a primary activation of the basolateral NCX1 [10, 34].
Inhibition of apical Na entry by thiazides would reduce
the intracellular Na concentration, resulting in stimula-
tion of NCX1 and in enhancement of basolateral Ca2
efflux. However, the significant down-regulation of
NCX1 transcripts during thiazide treatment shown in
this study does not seem consistent with the proposed
stimulation of Na/Ca2 exchange activity. Furthermore,
calbindin-D28K mRNA and protein abundance were also
decreased during HCTZ treatment. Calbindin-D28K facil-
itates diffusion of Ca2 through the cytosol and simulta-
neously serves as an intracellular Ca2 buffer to protect
the cell from toxic Ca2 levels [35]. This substantial de-
crease of the Ca2 diffusion and buffering capacity would
be detrimental in the presence of increased apical Ca2
entry and increased transcellular Ca2 transport. Fur-
thermore, both hypotheses imply a significant colocaliza-
tion of NCC and the Ca2 transport proteins in the DCT.
The present study shows that the population of tubules
held responsible for the thiazide-related enhancement of
Ca2 reabsorption is dramatically reduced during HCTZ
treatment. Thus, the consistently decreased expression
of the Ca2 transporters seems at variance with a direct
stimulation of active Ca2 transport processes during
chronic thiazide treatment.
An additional question emerging from our data is how
this decreased expression of the Ca2 transporters in all
HCTZ-treated groups can be explained. This reduction
in the expression was accompanied by a comparable
reduction in NCC abundance, which was confirmed by
loss of tubules coexpressing Ca2 transporters and NCC.
These findings suggest a thiazide-specific deleterious ef-
fect on DCT. This would explain the decreased expres-
sion levels consistently obtained in all HCTZ-treated
groups, regardless of ECV status and calciuresis. Impor-
tant in this respect is the finding by Loffing et al [22]
that thiazide treatment induces structural degeneration
of DCT cells and apoptotic cell death, apparent on light
and electron microscopy, which is accompanied by a
decreased amount of NCC mRNA transcripts. Further-
more, they showed that in degenerating cells NCC immu-
nostaining was virtually absent in the apical membrane,
but accumulated in the cytoplasm [22]. In line with their
data is the present, albeit less frequent, observation of
a similar disturbed cellular localization of NCC in all
HCTZ-treated rats, which was never encountered in con-
trols. This atypical, intracellular distribution might be the
result of structural damage, suggesting advanced cellular
degeneration. In contrast, a recently published study
showed that thiazides can increase NCC expression lev-
els [36]. These authors could not explain this discrepancy.
Nevertheless, the present data suggest that thiazides in-
duce structural damage to and loss of DCT cells, ex-
plaining the reduced expression of transporters present
in this nephron segment (i.e., TRPV5, calbindin-D28K,
NCX1, and NCC).
Alternatively, the decreased expression levels could
result from a compensatory down-regulation to counter-
act a positive Ca2 balance. Indeed, the reduced Ca2
excretion in thiazide treatment is reported to be accom-
panied by a small, transient rise in plasma Ca2 concen-
tration [37]. This would result in a compensatory decrease
of plasma PTH and calcitriol levels in an effort to normalize
plasma Ca2. Reduced calcitriol concentrations have
been reported during thiazide treatment [38–40] and ex-
pression of the proteins involved in active Ca2 transport
is positively regulated by calcitriol [16, 41]. Therefore,
compensatory down-regulation of the Ca2 transport pro-
teins might ensue. This suggestion is, however, at vari-
ance with our findings that reversal of hypocalciuria by
Na repletion did not normalize the expression levels
of the transporters and that their expression was not
affected in the Na-depleted animals, which exhibit overt
hypocalciuria.
In Gitelman syndrome, a recessive disorder caused by
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mutations in the gene encoding NCC, hypocalciuria is
invariably present [20, 42]. Current hypotheses concern-
ing the mechanism responsible for this hypocalciuria also
center on stimulation of active Ca2 transport [11].
Therefore, results from the present study could be appli-
cable to explain the hypocalciuria in Gitelman syndrome.
For instance, Gitelman patients are hyperreninemic, hav-
ing significantly lower blood pressures compared to their
unaffected relatives, and in mice harboring a NCC null
mutation, kidney renin mRNA levels are elevated
[11, 43]. This indicates that compensatory mechanisms
to correct hypovolemia are activated. In addition, in
NCC null mice, a more than threefold decrease of readily
identifiable DCT cells was observed, showing that the
absence of functional NCC is not well tolerated by a
major population of DCT cells, leading to significant
structural changes [20]. This implies that, like during
chronic thiazide treatment in our study, the population
of cells supposedly harboring the hypocalciuric mecha-
nism is decreased. Therefore, similar experiments in
NCC knockout mice might add important new data in
unraveling the mechanism responsible for the hypo-
calciuria in Gitelman syndrome.
CONCLUSION
The consistent down-regulation of proteins involved in
active Ca2 transport as well as the observed deleterious
effects of HCTZ on DCT cells do not support a stimula-
tion of active Ca2 transport during chronic thiazide
treatment. Our data suggest that ECV contraction is a
critical determinant of the hypocalciuric effect of chronic
thiazide treatment. Detailed and elaborate micropunc-
ture experiments are needed to measure the rate of Ca2
reabsorption in the distal convoluted and connecting tu-
bules during chronic thiazide-induced hypocalciuria.
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